This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coughlan, M. T. Articles by Forbes, J. M. Search for Related Content PubMed PubMed Citation Articles by Coughlan, M. T. Articles by Forbes, J. M.

Combination Therapy with the Advanced Glycation End Product Cross-Link Breaker, Alagebrium, and Angiotensin Converting Enzyme Inhibitors in Diabetes: Synergy or Redundancy?

Albert Einstein Juvenile Diabetes Research Foundation Centre for Diabetes Complications (M.T.C., V.T.-B., J.P., D.M.L., A.G., D.C.K.T., M.A., M.E.C., J.M.F.), Wynn Domain, Baker Medical Research Institute, Melbourne, Victoria 8008, Australia; Department of Chemistry and Biochemistry (S.R.T.), University of South Carolina, Columbia, South Carolina 29208; and Department of Immunology (M.E.C., J.M.F.), Monash University, Alfred Medical Research and Education Precinct, Melbourne, Victoria 3004, Australia

Address all correspondence and requests for reprints to: Dr. M. T. Coughlan, Albert Einstein Juvenile Diabetes Research Foundation Centre for Diabetes Complications, Wynn Domain, Baker Medical Research Institute, P.O. Box 6492, St. Kilda Road Central, Melbourne, Victoria 8008, Australia. E-mail: melinda.coughlan{at}baker.edu.au.

Blockade of advanced glycation end product (AGE) accumulation with alagebrium with concomitant angiotensin converting enzyme inhibition was tested for effects on renal function and on other postulated mediators of diabetic renal disease including the renin-angiotensin system, AGEs, mitochondrial and cytosolic oxidative stress, and intracellular signaling molecules. Sprague Dawley rats were rendered diabetic with streptozocin and followed consecutively for 32 wk with nondiabetic controls. Groups were treated with ramipril (1 mg/kg·d; wk 0–32); alagebrium (10 mg/kg·d; wk 16–32); or a combination of both. Although individual treatments had significant effects on albuminuria, no further improvements were seen with combination therapy. Changes in urinary vascular endothelial growth factor excretion mirrored those seen in albuminuria. Diabetes was associated with suppression of circulating angiotensin II in the context of increased circulating and renal levels of the AGE, carboxymethyllysine. All treatments attenuated circulating but not renal carboxymethyllysine levels. The renal gene expression of AGE receptor 1 and soluble receptor for advanced glycation end products were markedly reduced by diabetes and normalized with alagebrium. Diabetes induced renal mitochondrial oxidative stress, which was reduced with alagebrium. In the cytosol, both therapies were equally effective in reducing reactive oxygen species production. Increases in membranous protein kinase C activity in diabetes were attenuated by all treatments, whereas diabetes-associated increases in nuclear factor-B p65 translocation remained unaltered by any therapy. It is evident that renin-angiotensin system blockade and AGE inhibition have specific effects. However, many of their downstream effects appear to be similar, suggesting that their renoprotective benefits may ultimately involve common pathways and key points of convergence, which could be important targets for new therapies in diabetic nephropathy.

This article has been cited by other articles:

				T. Fujimura, S.-i. Yamagishi, S. Ueda, K. Fukami, R. Shibata, Y. Matsumoto, Y. Kaida, A. Hayashida, K. Koike, T. Matsui, et al. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1397 - 1406. [Abstract] [Full Text] [PDF]

				M. T. Coughlan, D. R. Thorburn, S. A. Penfold, A. Laskowski, B. E. Harcourt, K. C. Sourris, A. L.Y. Tan, K. Fukami, V. Thallas-Bonke, P. P. Nawroth, et al. RAGE-Induced Cytosolic ROS Promote Mitochondrial Superoxide Generation in Diabetes J. Am. Soc. Nephrol., April 1, 2009; 20(4): 742 - 752. [Abstract] [Full Text] [PDF]

				J. H. Garman, S. Mulroney, M. Manigrasso, E. Flynn, and C. Maric Omega-3 fatty acid rich diet prevents diabetic renal disease Am J Physiol Renal Physiol, February 1, 2009; 296(2): F306 - F316. [Abstract] [Full Text] [PDF]

				C. Tikellis, M. C. Thomas, B. E. Harcourt, M. T. Coughlan, J. Pete, K. Bialkowski, A. Tan, A. Bierhaus, M. E. Cooper, and J. M. Forbes Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E323 - E330. [Abstract] [Full Text] [PDF]

				V. Thallas-Bonke and J. M. Forbes Response to Comment on: Thallas-Bonke et al. (2008) Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product-Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-{alpha}-Dependent Pathway: Diabetes 57:460-469, 2008 Diabetes, June 1, 2008; 57(6): e14 - e14. [Full Text] [PDF]

				J. M. Forbes, M. T. Coughlan, and M. E. Cooper Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes Diabetes, June 1, 2008; 57(6): 1446 - 1454. [Abstract] [Full Text] [PDF]

				V. Thallas-Bonke, S. R. Thorpe, M. T. Coughlan, K. Fukami, F. Y.T. Yap, K. C. Sourris, S. A. Penfold, L. A. Bach, M. E. Cooper, and J. M. Forbes Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product-Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-{alpha}-Dependent Pathway Diabetes, February 1, 2008; 57(2): 460 - 469. [Abstract] [Full Text] [PDF]